Arvinas, Inc.

Equities

ARVN

US04335A1051

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-05-24 EDT 5-day change 1st Jan Change
35.23 USD 0.00% Intraday chart for Arvinas, Inc. +7.80% -14.41%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Arvinas, Inc. Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress CI
Sector Update: Health Care Stocks Steady Premarket Thursday MT
Sector Update: Health Care MT
Correction: Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity MT
Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity MT
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib CI
Transcript : Arvinas, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:00 PM
Oppenheimer Adjusts Arvinas Price Target to $70 From $80, Maintains Outperform Rating MT
Arvinas Shares Up After Q1 Net Loss Narrows MT
Earnings Flash (ARVN) ARVINAS Reports Q1 Revenue $25.3M MT
Arvinas, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Arvinas, Inc. Appoints Randy Teel as Chief Business Officer CI
H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating MT
HC Wainwright Adjusts Arvinas' Price Target to $87 From $90, Keeps Buy Rating MT
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug MT
Wedbush Adjusts Arvinas' Price Target to $57 From $59, Keeps Outperform Rating MT
Novartis: licensing agreement in prostate cancer CF
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis MT
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact DJ
Novartis licenses Arvinas' cancer drug for up to $1 billion RE
Arvinas, Inc Enters into an Exclusive Strategic License Agreement with Novartis AG for the Development and Commercialization of Protac Androgen Receptor Protein Degrader Arv-766 for the Treatment of Prostate Cancer CI
Arvinas Appoints Noah Berkowitz as Chief Medical Officer MT
Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee CI
Transcript : Arvinas, Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 09:00 AM
Barclays Adjusts Arvinas' Price Target to $60 From $26, Maintains Overweight Rating MT
Chart Arvinas, Inc.
More charts
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
35.23 USD
Average target price
68.44 USD
Spread / Average Target
+94.28%
Consensus
  1. Stock Market
  2. Equities
  3. ARVN Stock
  4. News Arvinas, Inc.
  5. Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis